Primary Progressive Multiple Sclerosis
A Randomized Placebo-controlled Trial Evaluating Laquinimod in PPMS, Gauging Gradations In MRI and Clinical Outcomes.–Teva
Purpose of the Study
• To find out whether laquinimod is safe and effective in reducing the loss of brain volume and reducing MS worsening
Participants must meet the following criteria
• Male or female between 25 to 55 years of age.
• Diagnosis of Primary Progressive Multiple Sclerosis
• Able to walk with or without the use of assistance
• Evidence of disability progression within the past 2 years
Study Design
• Study will last approximately 1.5 up to 2.5 years
• 8 visits to the study center
• 2 out of 3 patients will be randomized to receive the study medication
Compensation
• You will be compensated $66.30 for each study visit you finish
• You may also be eligible to receive $41.65 for travel and parking for each study visit you finish.
Relapsing Forms of Multiple Sclerosis
Multicenter, Randomized, Double-Blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects with Relapsing Multiple Sclerosis.–Acetelion
Purpose of the Study
• To evaluate the effect of ponesimod on your disease in comparison to that of teriflunomide
Participants must meet the following criteria
• Male or female between 18 to 55 years of age.
• Diagnosis of MS (RRMS or SPMS with relapses)
• Able to walk without assistance
• Experienced 1 or more documented MS attacks within the past year, or 2 or more within the past 2 years
Study Design
• Study will last up to 2 years and 4 months
• 16 visits to the study center
• You will have equal chance for either Ponesimod or Teriflunomide
Compensation
• You will be compensated $50.00 for each study visit you finish
Relapsing-Remitting Multiple Sclerosis
A 12-Month, Randomized, Rater- and Dose-blinded study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily with Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients with Relapsing-remitting Multiple Sclerosis–CFTY720D2312
Purpose of the Study
• To compare 2 doses of fingolimod with glatiramer acetate 20 mg and to evaluate the effectiveness and safety of fingolimod 0.25 mg for people with RRMS
Participants must meet the following criteria
• Male or female between 18 to 65 years of age.
• Diagnosis of Relapsing Remitting Multiple Sclerosis
• Able to walk with or without the use of assistance
• Experienced 1 or more documented MS attacks within the past year, or 2 or more within the past 2 years
Study Design
• Screening period up to 45 days followed by dosing period of 12 months. Follow-up visits every 3 months until after the last dose of study drug for all participants
• Random assignment to receive fingolimod 0.25 mg, fingolimod 0.5 mg, or glatiramer acetate 20 mg
Compensation
• You will be compensated up to $750.00 if you complete the whole study.
Apply for this Study or Request More Information
Neuromyelitis Optica (NMO)
NEUROMYELITIS OPTICA (NMO)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patietns with Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)–Chugai
Purpose of the Study
• To evaluate the effectiveness and safety of a subcutaneous injection of SA237 in patients with NMO or NMOSD
Participants must meet the following criteria
• Male or female between 18 to 74 years of age.
• Diagnosis of NMO or NMOSD
• Able to walk with or without the use of assistance
• Evidence of 1 disease attack in the last 12 months
Study Design
• Study consists of a screening period followed by a double-blind period. You will also have the option to enter an extension period
• 2 out of 3 patients will be assigned to SA237 and 1 out of 3 patients will be assigned to placebo
Compensation
• You will be compensated up to $58.00 for each visit attended
Apply for this Study or Request More Information
SUNPHARMA
Spacity and Multiple Sclerosis
SPASTICITY AND MULTIPLE SCLEROSIS
Study 1: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial to Evaluate the Duration of Action of Baclofen ER Capsules (GRS) in Subjects with Spasticity due to Multiple Sclerosis (MS)
Study 2: A Placebo-Controlled Randomized Withdrawal Evaluation of the Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects with Spasticity Due to Multiple Sclerosis
Study 3: A Clinical Evaluation of the Safety of Baclofen ER Capsules (GRS) When Administered Once Daily to Subjects with Spasticity Due to Multiple Sclerosis (MS): An Open Label, Long Term, Safety Trial–Sunpharma
Purpose of the Study
• To evaluate Baclofen ER Capsules in individuals with MS due to spasticity
Participants must meet the following criteria
• Men and women age 18 years and older
• Diagnosis of Multiple Sclerosis
• Known history of Spasticity (muscle stiffness) due to MS
• On a stable dose of Baclofen IR for the last 30 days or a history of spasticity but no previous exposure to baclofen treatment
Study Design
• Three separate studies are available, each with a different design and purpose. Please contact our study site to determine which study is best for you.
Compensation
• Compensation for time and travel will be provided.
Apply for this Study or Request More Information